JO3701B1 - مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي - Google Patents

مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي

Info

Publication number
JO3701B1
JO3701B1 JOP/2015/0107A JOP20150107A JO3701B1 JO 3701 B1 JO3701 B1 JO 3701B1 JO P20150107 A JOP20150107 A JO P20150107A JO 3701 B1 JO3701 B1 JO 3701B1
Authority
JO
Jordan
Prior art keywords
mers
cov
antibodies
bind
spike protein
Prior art date
Application number
JOP/2015/0107A
Other languages
Arabic (ar)
English (en)
Inventor
Sivapalasingam Sumathi
Stahl Neil
Kyratsous Christos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3701(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3701B1 publication Critical patent/JO3701B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/102—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JOP/2015/0107A 2014-05-23 2015-05-07 مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي JO3701B1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462002233P 2014-05-23 2014-05-23
US201462004971P 2014-05-30 2014-05-30
US201462051717P 2014-09-17 2014-09-17
US201462072716P 2014-10-30 2014-10-30

Publications (1)

Publication Number Publication Date
JO3701B1 true JO3701B1 (ar) 2021-01-31

Family

ID=53276323

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0107A JO3701B1 (ar) 2014-05-23 2015-05-07 مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي

Country Status (19)

Country Link
US (3) US9718872B2 (enExample)
EP (1) EP3145539A1 (enExample)
JP (4) JP6934722B2 (enExample)
KR (1) KR102371300B1 (enExample)
CN (2) CN114057869B (enExample)
AU (1) AU2015264189B2 (enExample)
BR (1) BR112016025009B1 (enExample)
CA (1) CA2949438A1 (enExample)
CL (1) CL2016002934A1 (enExample)
EA (1) EA036023B1 (enExample)
IL (1) IL248392B2 (enExample)
JO (1) JO3701B1 (enExample)
MA (1) MA40688A (enExample)
MX (1) MX373581B (enExample)
MY (1) MY180741A (enExample)
PH (1) PH12016502064A1 (enExample)
SG (1) SG11201608567YA (enExample)
WO (1) WO2015179535A1 (enExample)
ZA (1) ZA201607047B (enExample)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
JO3701B1 (ar) * 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
CN106928326B (zh) * 2015-12-31 2019-12-24 中国科学院微生物研究所 一种基于二聚化的受体结合区亚单位的冠状病毒疫苗
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN107298712B (zh) * 2016-04-14 2020-04-07 中国疾病预防控制中心病毒病预防控制所 全人源化抗中东呼吸综合征冠状病毒中和抗体
TW201815821A (zh) * 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
JP2019529350A (ja) 2016-08-16 2019-10-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 混合物から個々の抗体を定量する方法
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
BR112019006689A2 (pt) 2016-10-25 2019-06-25 Regeneron Pharma métodos e sistemas para análise de dados de cromatografia
KR20180058206A (ko) * 2016-11-23 2018-05-31 에스케이케미칼 주식회사 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
EP3570668A1 (en) * 2017-01-19 2019-11-27 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
KR20200010390A (ko) 2017-05-22 2020-01-30 에프. 호프만-라 로슈 아게 치료 화합물 및 조성물, 및 이의 사용 방법
KR20250041082A (ko) 2017-07-06 2025-03-25 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
KR101895228B1 (ko) * 2017-08-23 2018-10-30 대한민국 중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도
KR102798879B1 (ko) 2017-09-19 2025-04-30 리제너론 파아마슈티컬스, 인크. 입자 형성을 감소시키는 방법 및 그것에 의해 형성된 조성물
US11230592B2 (en) 2017-09-27 2022-01-25 The Wistar Institute Of Anatomy And Biology DNA antibody constructs for use against middle east respiratory syndrome coronavirus
WO2019078600A1 (ko) * 2017-10-19 2019-04-25 (주)에이티젠 중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
EP3727629A1 (en) 2017-12-22 2020-10-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
WO2019151632A1 (ko) * 2018-01-31 2019-08-08 (주)셀트리온 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
JP7349998B2 (ja) 2018-01-31 2023-09-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法
KR20190093107A (ko) * 2018-01-31 2019-08-08 (주)셀트리온 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
JP2021514609A (ja) 2018-02-28 2021-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ウイルス混入物質を同定するためのシステムおよび方法
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
MY202358A (en) 2018-03-19 2024-04-24 Regeneron Pharma Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
CN110616198B (zh) * 2018-06-19 2021-02-19 清华大学 一种基于黑猩猩腺病毒68型和MERS-CoV全长膜蛋白的新型冠状病毒疫苗
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
KR102682192B1 (ko) * 2018-08-17 2024-07-04 한림대학교 산학협력단 메르스 코로나바이러스 s 단백질에 대한 단클론 항체 및 그 용도
EP3774841A1 (en) 2018-08-27 2021-02-17 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
CA3100038A1 (en) 2018-08-30 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
RU2709659C1 (ru) * 2018-09-06 2019-12-19 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Иммунобиологическое средство и способ его использования для индукции специфического иммунитета к вирусу ближневосточного респираторного синдрома (варианты)
KR102007161B1 (ko) * 2018-11-07 2019-08-07 대한민국 메르스 코로나 바이러스 스파이크 s1 단백질에 특이적으로 결합하는 단클론 항체
BR112021009543A2 (pt) 2019-01-16 2021-08-17 Regeneron Pharmaceuticals, Inc. métodos para identificar tióis livres em um medicamento de proteína, de identificação de heterogeneidade de dissulfeto em um medicamento de proteína e para selecionar um medicamento de proteína, e, composição farmacêutica
CN113874394B (zh) * 2019-02-20 2024-01-19 和铂抗体有限公司 抗体
US11364276B2 (en) 2019-03-26 2022-06-21 National Guard Health Affairs Antiviral peptides for treatment of the middle east respiratory syndrome
CN118064502A (zh) * 2019-04-03 2024-05-24 瑞泽恩制药公司 用于将抗体编码序列插入到安全港基因座中的方法和组合物
KR102213745B1 (ko) * 2019-04-16 2021-02-09 주식회사 바이오앱 돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법
SG11202110911RA (en) 2019-05-13 2021-10-28 Regeneron Pharma Improved competitive ligand binding assays
WO2021060837A1 (en) * 2019-09-23 2021-04-01 Seoul National University R&Db Foundation Anti-mers-cov antibody and use thereof
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
US11730793B2 (en) 2019-11-25 2023-08-22 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
WO2021150558A1 (en) 2020-01-21 2021-07-29 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CA3163164A1 (en) 2020-02-10 2021-08-19 Alina Baum Anti-tmprss2 antibodies and antigen-binding fragments
BR112022015707A2 (pt) * 2020-02-10 2022-09-27 Inst Microbiology Cas Antígenos de beta-coronavírus, métodos de preparação e usos dos mesmos
DK3872091T5 (da) 2020-02-26 2024-08-12 Vir Biotechnology Inc Antistoffer mod sars-cov-2
CN113321713B (zh) * 2020-02-28 2022-11-01 深圳市亚辉龙生物科技股份有限公司 SARS-CoV-2的重组RBD蛋白及其制备方法
MX2022011142A (es) * 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticuerpos anti-coronavirus y metodos de uso.
US20210283243A1 (en) * 2020-03-11 2021-09-16 Ibio, Inc. Lichenase-covid-19 based vaccine
CN115484964B (zh) * 2020-03-12 2024-03-15 S·D·卡利斯-希尔 冠状病毒感染和相关细胞因子毒性的治疗
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
WO2021207948A1 (en) * 2020-04-14 2021-10-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-sars-cov-2 antibodies and uses thereof
PL4045533T3 (pl) 2020-03-26 2024-04-15 Vanderbilt University Ludzkie przeciwciała monoklonalne przeciwko ciężkiemu ostremu zespołowi oddechowemu wywołanemu koronawirusem 2 (sars-cov-2)
WO2021201679A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting coronaviruses
KR20230005850A (ko) * 2020-04-01 2023-01-10 티오제네시스 테라퓨틱스, 인크. 베타코로나바이러스 감염의 치료를 위한 시스테아민 전구체 화합물
SG11202103404PA (en) 2020-04-02 2021-04-29 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021216876A2 (en) * 2020-04-24 2021-10-28 The Board Of Regents Of The University Of Texas System Antibodies to coronavirus spike protein and methods of use thereof
JP7778685B2 (ja) * 2020-04-30 2025-12-02 富士フイルム富山化学株式会社 ピラジン誘導体と他のコロナウイルス感染症治療薬とを組み合わせてなるコロナウイルス感染症治療剤
GB202007532D0 (en) * 2020-05-20 2020-07-01 Alchemab Therapeutics Ltd Polypeptides
WO2021238910A1 (en) * 2020-05-25 2021-12-02 Guo Bingshi Anti-coronavirus spike protein antibodies and uses thereof
BR112022024149A2 (pt) * 2020-05-26 2023-02-07 Regeneron Pharma Anticorpos antiglicoproteína spike de anti-sars-cov-2 e fragmentos de ligação a antígeno
CN111606981B (zh) * 2020-05-27 2022-02-08 中国医学科学院基础医学研究所 Sars-cov冠状病毒s1蛋白多肽及其应用
US11999777B2 (en) 2020-06-03 2024-06-04 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies
US20230227539A1 (en) * 2020-06-16 2023-07-20 Hifibio (Hk) Limited Methods and compositions related to neutralizing antibodies against human coronavirus
WO2021260075A1 (en) * 2020-06-23 2021-12-30 Navigo Proteins Gmbh Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (sars-cov-2)
WO2022019711A1 (ko) * 2020-07-24 2022-01-27 (주)셀트리온 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자
WO2022026807A2 (en) * 2020-07-30 2022-02-03 Albert Einstein College Of Medicine Antibodies targeting sars-cov-2 and uses thereof
JP2023537470A (ja) * 2020-08-03 2023-09-01 ヤンセン バイオテツク，インコーポレーテツド ウイルス治療における多方向バイオ輸送のための材料及び方法
US20230357365A1 (en) * 2020-08-07 2023-11-09 Novelgen Co., Ltd. Antiviral composition against coronavirus
BR112023003273A2 (pt) 2020-08-31 2023-05-02 Regeneron Pharma Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
WO2022054068A1 (en) * 2020-09-14 2022-03-17 Ramot At Tel-Aviv University Ltd. Antibodies for the prevention, treatment and detection of coronavirus infection
CA3192706A1 (en) * 2020-09-15 2022-03-24 Gregory SEMPOWSKI Coronavirus antibodies and uses thereof
EP4217386A4 (en) * 2020-09-24 2025-01-15 The Broad Institute, Inc. PLATFORM FOR ENGINEERING CELL-FREE ANTIBODIES AND NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2
CN112379087B (zh) * 2020-10-21 2022-02-11 中国医学科学院医学生物学研究所 一种应用于新型冠状病毒灭活疫苗的裂解液及抗原解离的方法
US12239687B2 (en) 2020-11-25 2025-03-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
US11834493B2 (en) 2021-01-05 2023-12-05 Immunome, Inc. Antibody cocktail against SARS-CoV-2 spike protein
CN114716541B (zh) * 2021-01-05 2023-07-21 中国科学院分子细胞科学卓越创新中心 抗冠状病毒的全人广谱中和抗体76e1及其应用
AU2022209730A1 (en) 2021-01-20 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
US20240101645A1 (en) * 2021-01-22 2024-03-28 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Monoclonal antibodies against coronaviruses and uses thereof
WO2022170126A2 (en) * 2021-02-05 2022-08-11 Adagio Therapeutics, Inc. Compounds specific to coronavirus s protein and uses thereof
WO2022182662A1 (en) 2021-02-23 2022-09-01 10X Genomics, Inc. Compositions and methods for mapping antigen-binding molecule affinity to antigen regions of interest
KR20230154020A (ko) * 2021-03-02 2023-11-07 노바록 바이오테라퓨틱스 리미티드 클라우딘-6에 대한 항체 및 이의 용도
BR112023017442A2 (pt) 2021-03-03 2023-09-26 Regeneron Pharma Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
EP4308589A4 (en) * 2021-03-15 2025-02-26 Emory University SARS-COV-2 ANTIBODIES AND FRAGMENTS, THERAPEUTIC USES, DIAGNOSTIC USES AND COMPOSITIONS RELATED THERETO
WO2022212654A2 (en) * 2021-04-02 2022-10-06 The Scripps Research Institute Cross-reactive monoclonal antibodies against coronaviruses
WO2022241200A1 (en) * 2021-05-14 2022-11-17 Vanderbilt University Cross-reactive coronavirus antibodies
EP4348234A1 (en) 2021-06-01 2024-04-10 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
TW202321292A (zh) 2021-07-14 2023-06-01 美商再生元醫藥公司 抗sars-cov-2-棘醣蛋白抗體及抗原結合片段
WO2023004431A2 (en) * 2021-07-23 2023-01-26 The Trustees Of Columbia University In The City Of New York Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use
WO2023039457A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
EP4405390A1 (en) 2021-09-20 2024-07-31 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
CN116178530A (zh) * 2021-09-26 2023-05-30 上海君实生物医药科技股份有限公司 抗体在治疗SARS-CoV-2感染的用途
CA3230984A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Systems and methods of ph modeling and control
WO2023059803A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
US20240409618A1 (en) * 2021-10-13 2024-12-12 The Wistar Institute Of Anatomy And Biology DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS
IL312372A (en) 2021-10-26 2024-06-01 Regeneron Pharma Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2023178182A1 (en) 2022-03-16 2023-09-21 10X Genomics, Inc. Compositions and methods for detection and treatment of coronavirus infection
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
TW202446462A (zh) 2023-02-22 2024-12-01 美商再生元醫藥公司 系統適用性參數及管柱老化
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
TW202535934A (zh) 2023-11-02 2025-09-16 美商再生元醫藥公司 利用應力來降低脂酶活性的方法
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
CN119264262B (zh) * 2024-09-19 2025-09-02 中山大学 一种双特异性抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
CA2522379C (en) * 2003-04-10 2012-10-23 Chiron Corporation The severe acute respiratory syndrome coronavirus
WO2005060520A2 (en) * 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
KR102010827B1 (ko) 2009-06-26 2019-08-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
WO2014045254A2 (en) 2012-09-23 2014-03-27 Erasmus University Medical Center Rotterdam Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor
CN103554244B (zh) * 2013-05-09 2016-09-07 香雪集团(香港)有限公司 具有抑制呼吸道病毒感染的活性的肽及其应用和制备方法
CN103554235B (zh) * 2013-06-17 2015-06-24 清华大学 MERS-CoV病毒膜蛋白中的RBD片段及其编码基因和应用
EP3134111B1 (en) * 2014-04-25 2022-06-08 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
EP2993977B1 (en) * 2014-05-30 2018-07-18 Regeneron Pharmaceuticals, Inc. Humanized dipeptidyl peptidase iv (dpp4) animals

Also Published As

Publication number Publication date
US20190351049A1 (en) 2019-11-21
EA201691877A1 (ru) 2017-03-31
JP2023085425A (ja) 2023-06-20
IL248392B1 (en) 2023-08-01
CN106414496B (zh) 2021-11-30
PH12016502064A1 (en) 2016-12-19
JP6934722B2 (ja) 2021-09-15
US20150337029A1 (en) 2015-11-26
JP7297814B2 (ja) 2023-06-26
EP3145539A1 (en) 2017-03-29
KR102371300B1 (ko) 2022-03-07
CA2949438A1 (en) 2015-11-26
MY180741A (en) 2020-12-08
NZ725885A (en) 2022-04-29
SG11201608567YA (en) 2016-11-29
CN114057869B (zh) 2025-06-24
MX2016015263A (es) 2017-03-23
IL248392B2 (en) 2023-12-01
AU2015264189A1 (en) 2016-11-17
KR20170005133A (ko) 2017-01-11
US10406222B2 (en) 2019-09-10
JP2024123027A (ja) 2024-09-10
JP2017524339A (ja) 2017-08-31
US9718872B2 (en) 2017-08-01
CN106414496A (zh) 2017-02-15
MX373581B (es) 2020-05-05
MA40688A (fr) 2017-03-28
US20170340728A1 (en) 2017-11-30
WO2015179535A1 (en) 2015-11-26
BR112016025009B1 (pt) 2022-08-02
EA036023B1 (ru) 2020-09-15
AU2015264189B2 (en) 2021-03-25
IL248392A0 (en) 2016-11-30
ZA201607047B (en) 2017-09-27
CN114057869A (zh) 2022-02-18
BR112016025009A2 (pt) 2017-10-24
JP2021129594A (ja) 2021-09-09
CL2016002934A1 (es) 2017-11-03
JP7500812B2 (ja) 2024-06-17

Similar Documents

Publication Publication Date Title
JO3701B1 (ar) مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
MX2020000960A (es) Anticuerpos anti-tigit.
MX385545B (es) Anticuerpos humanos para pd-1.
PL3176181T3 (pl) Przeciwciało monoklonalne anty-CTLA4 lub jego fragment wiążący antygen, kompozycja lecznicza i zastosowanie
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
EA201791093A1 (ru) Антитела к cd47, способы и применение
MX392098B (es) Anticuerpos neutralizantes de poliomavirus.
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
EP3389699A4 (en) CHIMERIC AND HUMANIZED MONOCLONAL ANTIBODIES TO HUMAN CTLA4 AND USES THEREOF
EA201792414A1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения
EA201792413A1 (ru) Антитела против cd71, активируемые антитела против cd71 и способы их применения
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
PH12019501425A1 (en) Human antibodies to s. aureus hemolysin a toxin
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
MY184189A (en) Methods of treating nail and scalp psoriasis
MX378749B (es) Agentes para neutralizacion de influenza.
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use